Loading clinical trials...
Loading clinical trials...
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients With Migraine - PIONEER-PEDS2
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Age
6 - 17 years
Sex
ALL
Healthy Volunteers
No
Central Research Associates
Birmingham, Alabama, United States
Rehabilitation & Neurological Services
Huntsville, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Perseverance Research Center
Scottsdale, Arizona, United States
Center for Neurosciences
Tucson, Arizona, United States
Arkansas Children's
Little Rock, Arkansas, United States
Core Healthcare Group
Cerritos, California, United States
Miller Children's & Women's Hospital Long Beach
Long Beach, California, United States
Sensa Health
Los Angeles, California, United States
Orange County Research Institute - Ontario
Ontario, California, United States
Start Date
June 30, 2020
Primary Completion Date
December 4, 2025
Completion Date
December 4, 2025
Last Updated
March 10, 2026
566
ACTUAL participants
Lasmiditan
DRUG
Lead Sponsor
Eli Lilly and Company
NCT06641466
NCT07018713
NCT04715685
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions